Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients (Q41712920)

From Wikidata

Jump to navigation Jump to search

scientific article published on June 2017

Language	Label	Description	Also known as
English	Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients	scientific article published on June 2017

Statements

scholarly article

1 reference

Europe PubMed Central

7 October 2017

7 references

14 March 2019

24 March 2019

17 June 2019

7 November 2019

6 July 2020

5 December 2020

7 February 2021

0 references

Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients (English)

1 reference

Europe PubMed Central

7 October 2017

cardiovascular disease

5 references

14 March 2019

24 March 2019

17 June 2019

7 November 2019

6 July 2020

5 references

14 March 2019

24 March 2019

17 June 2019

7 November 2019

6 July 2020

2 references

7 November 2019

7 February 2021

carboxylic acid

1 reference

7 November 2019

1 reference

6 July 2020

cardiovascular agent

1 reference

5 December 2020

Alistair J Roddick

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28844155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28844155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Sean L Zheng

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28844155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

0 references

publication date

1 June 2017

1 reference

Europe PubMed Central

7 October 2017

1 September 2017

7 references

14 March 2019

24 March 2019

17 June 2019

7 November 2019

6 July 2020

5 December 2020

7 February 2021

Diabetes and Vascular Disease Research

8 references

14 March 2019

24 March 2019

17 June 2019

7 November 2019

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28844155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

6 July 2020

5 December 2020

7 February 2021

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28844155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

400-406

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28844155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28844155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

copyright license

Creative Commons Attribution 4.0 International

7 references

Europe PubMed Central

14 March 2019

Europe PubMed Central

24 March 2019

Europe PubMed Central

17 June 2019

Europe PubMed Central

7 November 2019

Europe PubMed Central

6 July 2020

Europe PubMed Central

5 December 2020

Europe PubMed Central

7 February 2021

copyright status

0 references

on focus list of Wikimedia project

0 references

Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5600262

6 June 2018

Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5600262

6 June 2018

Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5600262

6 June 2018

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5600262

6 June 2018

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5600262

6 June 2018

Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5600262

6 June 2018

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5600262

6 June 2018

The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5600262

6 June 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5600262

6 June 2018

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5600262

6 June 2018

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5600262

18 August 2018

Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5600262

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5600262

18 August 2018

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5600262

18 August 2018

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5600262

18 August 2018

Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren

1 reference

https://api.crossref.org/works/10.1177%2F1479164117715854

21 January 2018

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28844155

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/28844155

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan: the ASSERTIVE double-blind, randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28844155

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1177/1479164117715854

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28844155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28844155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28844155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41712920&oldid=1926211849"